Drug Type Small molecule drug |
Synonyms (2S,5R,6R)-6-({[3-(2-chlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, (3-(o-chlorophenyl)-5-methyl-4-isoxazolyl)penicillin, 6-(3-(o-chlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid + [10] |
Target |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CA (31 Dec 1963), |
Regulation- |
Molecular FormulaC19H20ClN3NaO6S |
InChIKeyKNNWTOJBVOKDPC-VICXVTCVSA-N |
CAS Registry7081-44-9 |
Start Date05 Jun 2022 |
Sponsor / Collaborator- |
Start Date11 Jul 2019 |
Sponsor / Collaborator |
Start Date05 May 2019 |
Sponsor / Collaborator |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02231 | Cloxacillin Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Staphylococcal Infections | CN | 01 Jan 1986 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |